Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.3.16 (
calcineurin
)
17,112
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Calcineurin is a serine/threonine
protein phosphatase
that plays a critical role in many physiologic processes, such as T-cell activation, apoptosis, skeletal myocyte differentiation, and cardiac hypertrophy. We determined that active MEKK3 was capable of activating
calcineurin
/nuclear factor of activated T-cells (NFAT) signaling in cardiac myocytes and reprogramming cardiac gene expression. In contrast, small interference RNA directed against MEKK3 and a dominant negative form of MEKK3 caused the reduction of NFAT activation in response to angiotensin II in cardiac myocytes. Genetic studies showed that MEKK3-deficient mouse embryo fibroblasts failed to activate
calcineurin
/NFAT in response to angiotensin II, a potent NFAT activator. Conversely, restoring MEKK3 to the MEKK3-deficient cells restored angiotensin II-mediated
calcineurin
/NFAT activation. We determined that angiotensin II induced MEKK3 phosphorylation. Thus, MEKK3 functions downstream of the AT1 receptor and is essential for
calcineurin
/NFAT activation. Finally, we determined that MEKK3-mediated activation of
calcineurin
/NFAT signaling was associated with the phosphorylation of
modulatory calcineurin-interacting protein 1
at Ser(108) and Ser(112). Taken together, our studies reveal a previously unrecognized novel essential regulatory role of MEKK3 signaling in
calcineurin
/NFAT activation.
...
PMID:The essential role of MEKK3 signaling in angiotensin II-induced calcineurin/nuclear factor of activated T-cells activation. 1612 26
The DSCR1 (
Adapt78
) gene is transiently induced by stresses to temporarily protect cells against further potentially lethal challenges. However, chronic expression of the DSCR1 (
Adapt78
) gene has now been implicated in several pathological conditions including Alzheimer's disease, Down syndrome and cardiac hypertrophy. Calcipressin 1 has been shown to function through direct binding and inhibition of the serine threonine
protein phosphatase
Calcineurin. Pharmacological inhibition of
calcineurin
, by the immunosuppressive drugs cyclosporin A and FK506, affects a wide variety of diseases. It is, therefore, likely that this endogenous calcineurin inhibitor,
calcipressin 1
, may also play a role in a variety of human diseases.
...
PMID:Multiple roles of the DSCR1 (Adapt78 or RCAN1) gene and its protein product calcipressin 1 (or RCAN1) in disease. 1623 Oct 93
Inhibition of the
calcineurin
-NFAT signalling pathway is one of the main challenges for immunosuppression therapy to avoid the severe side effects of the current anticalcineurinic drugs, cyclosporin A and FK506. The members of the calcipressin family are endogenous inhibitors of
calcineurin
. We describe for the first time that two independent motifs within human
calcipressin 1
, the ELHA and the PxIxxT motifs, interact with
calcineurin
in an independent functional manner. However, the main finding here is that the ELHA-containing
calcineurin
-inhibitor CALP1 (CIC) motif is the responsible for the in vivo inhibition of
calcineurin
-mediated NFAT-dependent cytokine gene expression in human T cells. We believe that the identification of the CIC motif could be used as a starting point for the development of new immunosuppressive drugs for use in transplantation and autoimmune diseases.
...
PMID:Functional characterization of the calcipressin 1 motif that suppresses calcineurin-mediated NFAT-dependent cytokine gene expression in human T cells. 1640 92
Calcineurin is a serine/threonine
protein phosphatase
that plays a critical role in many physiologic processes such as T-cell activation, skeletal myocyte differentiation, and cardiac hypertrophy. We previously showed that active MEKK3 is capable of stimulating
calcineurin
/nuclear factor of activated T-cells (NFAT) signaling in cardiac myocytes through phosphorylation of
modulatory calcineurin-interacting protein 1
(
MCIP1
). However, the protein kinases that function downstream of MEKK3 to mediate
MCIP1
phosphorylation and the mechanism of
MCIP1
-mediated
calcineurin
regulation have not been defined. Here, we show that MEK5 and big MAP kinase 1 (BMK1) function downstream of MEKK3 in a signaling cascade that induces
calcineurin
activity through phosphorylation of
MCIP1
. Genetic studies showed that BMK1-deficient mouse lung fibroblasts failed to mediate
MCIP1
phosphorylation and activate
calcineurin
/NFAT in response to angiotensin II, a potent NFAT activator. Conversely, restoring BMK1 to the deficient cells restored angiotensin II-mediated
calcineurin
/NFAT activation. Thus, using BMK1-deficient mouse lung fibroblast cells, we provided the genetic evidence that BMK1 is required for angiotensin II-mediated
calcineurin
/NFAT activation through MICP1 phosphorylation. Finally, we discovered that phosphorylated
MCIP1
dissociates from
calcineurin
and binds with 14-3-3, thereby relieving its inhibitory effect on
calcineurin
activity. In summary, our findings reveal a previously unrecognized essential regulatory role of mitogen-activated protein kinase signaling in
calcineurin
activation through the reversible phosphorylation of a
calcineurin
-interacting protein,
MCIP1
.
...
PMID:Protein kinase-mediated regulation of calcineurin through the phosphorylation of modulatory calcineurin-interacting protein 1. 1641 48
The
RCAN1 protein
(previously called
calcipressin 1
or MCIP1) binds to
calcineurin
, a serine/threonine phosphatase (PP2B), and inhibits its activity. Here we demonstrate that regulated overexpression of an
RCAN1
transgene (this gene was previously called DSCR1 or
Adapt78
) also stimulates expression of the GSK-3beta kinase, which can antagonize the action of
calcineurin
. We also show that GSK-3beta is regulated by
RCAN1
at a post-transcriptional level. In humans, high
RCAN1
expression is found in the brain, where at least two mRNA isoforms have been reported. Therefore, we further investigated expression of the various
RCAN1
isoforms, resulting from differential splicing and alternative promotors in human brain. We detected at least three distinct RCAN1s:
RCAN1
-1 Short at 31 kDa (RCAN1-1S),
RCAN1
-1 Long at 38 kDa (RCAN1-1 L), and
RCAN1
-4. Furthermore, the levels of
RCAN1
-1S, but not
RCAN1
-1 L or
RCAN1
-4 correlated with the levels of GSK-3beta. This suggests that
RCAN1
-1S might induce production of GSK-3beta in vivo. While RCAN1s can regulate
calcineurin
and GSK-3beta, it has also been shown that
calcineurin
and GSK-3beta can regulate RCAN1s. Here we propose a new model (incorporating all these findings) in which cells maintain an equilibrium between RCAN1s,
calcineurin
, and GSK-3beta.
...
PMID:RCAN1 (DSCR1 or Adapt78) stimulates expression of GSK-3beta. 1664 88
Hyperphosphorylated tau proteins accumulate in the paired helical filaments of neurofibrillary tangles seen in such tauopathies as Alzheimer's disease. In the present paper we show that tau turnover is dependent on degradation by the proteasome (inhibited by MG132) in HT22 neuronal cells. Recombinant human tau was rapidly degraded by the 20 S proteasome in vitro, but tau phosphorylation by GSK3beta (glycogen synthase kinase 3beta) significantly inhibited proteolysis. Tau phosphorylation was increased in HT22 cells by OA [okadaic acid; which inhibits PP (
protein phosphatase
) 1 and PP2A] or CsA [cyclosporin A; which inhibits PP2B (
calcineurin
)], and in PC12 cells by induction of a tet-off dependent
RCAN1
transgene (which also inhibits PP2B). Inhibition of PP1/PP2A by OA was the most effective of these treatments, and tau hyperphosphorylation induced by OA almost completely blocked tau degradation in HT22 cells (and in cell lysates to which purified proteasome was added) even though proteasome activity actually increased. Many tauopathies involve both tau hyperphosphorylation and the oxidative stress of chronic inflammation. We tested the effects of both cellular oxidative stress, and direct tau oxidative modification in vitro, on tau proteolysis. In HT22 cells, oxidative stress alone caused no increase in tau phosphorylation, but did subtly change the pattern of tau phosphorylation. Tau was actually less susceptible to direct oxidative modification than most cell proteins, and oxidized tau was degraded no better than untreated tau. The combination of oxidative stress plus OA treatment caused extensive tau phosphorylation and significant inhibition of tau degradation. HT22 cells transfected with tau-CFP (cyan fluorescent protein)/tau-GFP (green fluorescent protein) constructs exhibited significant toxicity following tau hyperphosphorylation and oxidative stress, with loss of fibrillar tau structure throughout the cytoplasm. We suggest that the combination of tau phosphorylation and tau oxidation, which also occurs in tauopathies, may be directly responsible for the accumulation of tau aggregates.
...
PMID:Phosphorylation inhibits turnover of the tau protein by the proteasome: influence of RCAN1 and oxidative stress. 1693 15
The regulators of
calcineurin
(RCAN) proteins, previously known as calcipressins, have been considered to be a well conserved family from yeast to human based on the conservation of their FLISPP motif. Here, after performing a RCAN comparative genomic analysis we propose the existence of a novel functionally closely related RCAN subfamily restricted to vertebrates, the other RCAN proteins being considered only as distantly related members of the family. In addition, while three paralogous RCAN genes are found in vertebrates, there is only one in the other members of Eukarya. Moreover, besides the FLISPP motif, these paralogous genes have two others conserved motifs, the Cn-inhibitor RCAN (CIC) and the PxIxxT, which are restricted to vertebrates. In humans,
RCAN1
and RCAN2 bind and inhibit Cn through their C-terminal region. Given the high amino acid identity in this region among human RCANs, authors in the field have hypothesized a role for RCAN3 in inhibiting Cn activity. Here, we demonstrate for the first time that human RCAN3, encoded by the RCAN3 (also known as DSCR1L2) gene, interacts physically and functionally with Cn. This interaction takes place only through the RCAN3 CIC motif. Overexpression of this sequence inhibits Cn activity towards the nuclear factor of activated T cells (NFAT) transcription factors and down-regulates NFAT-dependent cytokine gene expression in activated human Jurkat T cells.
...
PMID:RCAN3, a novel calcineurin inhibitor that down-regulates NFAT-dependent cytokine gene expression. 1727 Feb 91
Oxidative stress (OS) underlies neuronal dysfunction in many neurodegenerative disorders. Regulator of Calcineurin 1 (
RCAN1
or DSCR1) is a dose-sensitive gene whose overexpression has been linked to Down syndrome (DS) and Alzheimer's disease (AD) neuropathology and to the response of cells to stress stimuli. Here, we show that
RCAN1
mRNA and protein expression are sensitive to OS in primary neurons, and we evaluate the involvement of
RCAN1
dosage in neuronal death induced by OS. We find that Rcan1(-/-) neurons display an increased resistance to damage by H(2)O(2), which can be reverted by
RCAN1
overexpression or by exogenous inhibitors of
calcineurin
. Although increased intracellular Ca(2+) concentration is an important factor in OS-mediated cell death, our results show that Ca(2+) loading after exposure to H(2)O(2) was similar in Rcan1(+/+) and Rcan1(-/-) neurons. Our data further suggest that CaN and NFAT signaling protect against OS in both Rcan1(+/+) and Rcan1(-/-) neurons. To explain the observed differential vulnerability, we therefore propose a mechanism downstream of H(2)O(2)-mediated Ca(2+) entry, involving
calcineurin
-NFAT signaling. These findings highlight the importance of
RCAN1
gene dosage in the modulation of cell survival and death pathways and suggest that changes in the amount of
RCAN1
could represent an important mechanism for regulating susceptibility to neurodegeneration, especially in DS and AD.
...
PMID:RCAN1 (DSCR1) increases neuronal susceptibility to oxidative stress: a potential pathogenic process in neurodegeneration. 1734 86
RCANs, also called Down Syndrome Critical Region-1 (DSCR1)-like proteins, Modulatory Calcineurin Interacting Proteins (MCIPs) or calcipressins, are regulators of
calcineurin
, a Ca(2+)-dependent
protein phosphatase
involved in several neuronal functions. Despite the potential importance of the RCAN proteins in brain physiology, very little is known about their relative abundance and distribution patterns in the central nervous system. In this study we report the expression and distribution of RCAN mRNA transcripts and proteins in the mouse brain. RT-PCR and Western blot analysis showed that all Rcan mRNAs (Rcan1-1, Rcan1-2, Rcan2-1, Rcan2-3 and Rcan3) and their corresponding protein products (
RCAN1
-L,
RCAN1
-S, RCAN2-L, RCAN2-S and RCAN3) are present in every adult mouse brain region examined. All protein isoforms are also expressed in these same brain regions at early postnatal stages. Within regions,
RCAN1
-L,
RCAN1
-S, RCAN2-L and RCAN3 are differentially expressed depending on the region and developmental stage, whereas RCAN2-S is distributed homogeneously. Detailed immunohistochemical analysis revealed significant differences in the cellular and subcellular distributions of RCAN proteins. In the adult,
RCAN1
was mainly expressed in the neuropil throughout the brain. Although at lower levels, RCAN3 was also detected throughout the neuropil. In contrast, RCAN2 was highly expressed in scattered neurons, in both the nucleus and the cytoplasm. Interestingly, RCAN2 is the only member of the RCAN family that was detected in glial cells. Finally, the expression patterns of RCANs at early postnatal stages differed from those of the adult, in different brain areas, in both their distributions and relative abundance, suggesting that the expression of these proteins could be regulated during neuronal differentiation. The nonoverlapping expression patterns of the RCAN proteins shown here highlight the existence of different physiological scenarios and therefore suggest different RCAN functional activities in the brain, depending on the cellular context and developmental stage.
...
PMID:Differential expression of members of the RCAN family of calcineurin regulators suggests selective functions for these proteins in the brain. 1776
RCAN1
(
Adapt78
) is an endogenous inhibitor of
calcineurin
, an important intracellular phosphatase that mediates many cellular responses to calcium.
RCAN1
is expressed in multiple organs, especially heart, skeletal muscle and brain. In brain, it is thought to be important due to its strong expression, developmental regulation, abundance of target protein (
calcineurin
), and putative links to multiple brain-related disorders. Surprisingly, however, few studies have examined
RCAN1 protein
expression here. This has led to some confusion in the field over the exact nature and cell-type expression of isoform 4, the more studied of the two major
RCAN1 protein
isoforms, in brain. Here we characterize
RCAN1
brain isoforms in more detail by assessing their size and distribution under conditions of calcium elevation, a hallmark of the isoform 4 response, and using rodent models to allow for more expanded analyses. We find that the 25-29kDa version of this protein, reported in many non-brain studies, is indeed also present in neurons, and most observable after calcium induction. We also observe that expression of isoform 4 is not specific to neurons, as both microglia and astrocyte cells in culture exhibit a strong induction of isoform 4 protein following calcium stress that is not observable in non-stressed tissue sections. Isoform 1 expression is also observable in a primary glial cell-type (rat microglia). Finally, our observations confirm previous reports of low or non-detectable constitutive isoform expression in non-stressed glia, and of a larger sized,
RCAN1
antibody-interacting species. These studies extend and complement previous studies on RCAN isoforms toward better understanding the role of
RCAN1
in brain function and as a potential new target for treating
calcineurin
-related brain disorders.
...
PMID:Brain expression of the calcineurin inhibitor RCAN1 (Adapt78). 1791 Sep 44
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>